Evaluation of the efficacy and safety of recombinant human thrombopoietin (rhTPO) at 300 U/kg/day for hematopoietic stem cell mobilization in autologous transplantation among acute leukemia patients
Age 18～65 years, regardless of gender.
Histopathologically confirmed acute leukemia with immunohistochemical validation
Sustained complete hematologic remission with documented minimal residual disease (MRD) negativity.
Eastern Cooperative Oncology Group (ECOG) performance status smaller than 2 and a life expectancy of more than 6 months
Liver dysfunction (alanine aminotransferase or bilirubin greater than two times the normal upper limit).
Renal dysfunction (creatinine or urea higher than 1.5 times the normal upper limit).
Any disease that could put patients at high risk, including but not limited to unstable cardiac disease, uncontrolled atrial fibrillation or hypertension, severe diabetic retinopathy
rhTPO aller- gies.